AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia

Shots:

• The P-III ASCEND study involves assessing of Calquence (acalabrutinib, 100mg, q2d) vs Rituximab + Idelalisib/Bendamustine in 310 previously treated patients in a ratio (1:1) with CLL
• The P-III ASCEND study resulted in meeting its 1EPs i.e, improvement in progression-free survival (PFS), increment in the time for the next treatment and is safe & tolerable
• Calquence (acalabrutinib) is a BTK inhibitor, inhibiting its activity in B-cells, currently being evaluated in 26 studies by AstraZeneca & Acerta Pharma and has received FDA’s accelerated approval for MCL with one prior therapy in Oct’17  

Click here to read full press release/ article | Ref: AstraZeneca | Image: Touch concept